1.3100
-0.0300
(-2.24%)
At close: January 30 at 4:00:01 PM EST
1.3200
+0.01
+(0.76%)
Pre-Market: 7:27:23 AM EST
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 9.09M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| RYALI SRIRAM Chief Financial Officer | Purchase at price 1.42 per share. | Direct | 24,651 | Jan 29, 2025 |
| FISCHESSER RYAN M Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Nov 20, 2024 |
| MCCLUNG BARBARA G Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 20, 2024 |
| HAURWITZ RACHEL E. PH.D. Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 20, 2024 |
| O'BYRNE JASON Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 20, 2024 |
| KANNER STEVEN B. Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 20, 2024 |
| KHAN RUHI AHMAD Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 20, 2024 |
| KANNER STEVEN B. Officer | Conversion of Exercise of derivative security at price 2.69 per share. | Direct | 82,252 | Feb 6, 2024 |
| HAURWITZ RACHEL E. PH.D. Chief Executive Officer | Conversion of Exercise of derivative security at price 2.96 per share. | Direct | 29,600 | Jun 8, 2023 |
| HAURWITZ RACHEL E. PH.D. Chief Executive Officer | Conversion of Exercise of derivative security at price 2.96 per share. | Direct | 29,600 | Mar 20, 2023 |
Related Tickers
BEAM Beam Therapeutics Inc.
27.28
+5.29%
EDIT Editas Medicine, Inc.
1.3700
+2.24%
NTLA Intellia Therapeutics, Inc.
10.51
+3.85%
VERV Verve Therapeutics, Inc.
7.41
-3.77%
PRME Prime Medicine, Inc.
2.8300
+2.91%
FATE Fate Therapeutics, Inc.
1.3700
+4.58%
ALLO Allogene Therapeutics, Inc.
1.9200
+4.35%
IPSC Century Therapeutics, Inc.
0.8500
+3.13%
ZNTL Zentalis Pharmaceuticals, Inc.
1.6600
-12.17%
KYTX Kyverna Therapeutics, Inc.
3.3100
+2.16%